3.6 Immunotherapy and hyposensitisation

Bee and wasp allergen extracts

Pharmalgen®
  • Bee venom extract
  • Wasp venom extract

Notes

  1. See NICE TA246 (February 2012)

Grass pollen extract

Grazax®
  • Oral lyophilisates 75,000 units (£74.78)

Indications

  • Seasonal allergic hay fever due to grass or tree pollen in patients who have failed to respond to anti-allergy drugs

Dose

  • Adult and child over 5 years, 1 tablet daily; start treatment at least 4 months before start of pollen season

Notes

  1. Treatment with Grazax® will not be continued longer than 3 years.
  2. Consultant initiated

Mepolizumab

Mepolizumab
  • Injection 100mg

Notes

  1. NICE TA431 Mepolizumab, as an add-on to optimised standard therapy, is recommended as an option for treating severe refractory eosinophilic asthma in adults (January 2017). Commissioned by NHS England.

Omalizumab

Omalizumab
  • Injection 150mg/ml pre-filled syringe 0.5ml, 1ml

Notes

  1. NICE TA278 Omalizumab is recommended for severe persistent allergic asthma (April 2013)
  2. NICE TA339 Omalizumab is recommended for previously treated chronic spontaneous urticaria (June 2015). Commissioned by NHS England.

 

Home > Formulary > Chapters > 3. Respiratory > 3.6 Immunotherapy and hyposensitisation

 

  • First line
  • Second line
  • Specialist
  • Hospital